Weekly Research Analysts’ Ratings Updates for Insmed (INSM)

Insmed (NASDAQ: INSM) recently received a number of ratings updates from brokerages and research firms:

• 6/16/2026 – Insmed was given a new $192.00 price target by Mizuho.
• 6/10/2026 – Insmed had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – Insmed had its “buy” rating reaffirmed by Roth Mkm.
• 6/8/2026 – Insmed had its price target lowered by JPMorgan Chase & Co. from $180.00 to $179.00. They now have an “overweight” rating on the stock.
• 6/5/2026 – Insmed had its price target lowered by Royal Bank Of Canada from $205.00 to $195.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Insmed had its price target lowered by Truist Financial Corporation from $205.00 to $185.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
• 5/8/2026 – Insmed had its price target lowered by Guggenheim from $230.00 to $226.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Insmed had its price target lowered by Royal Bank Of Canada from $220.00 to $205.00. They now have an “outperform” rating on the stock.
• 5/8/2026 – Insmed had its price target lowered by Wells Fargo & Company from $177.00 to $160.00. They now have an “overweight” rating on the stock.

Insider Transactions at Insmed

In other Insmed news, COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This trade represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total value of $173,050.92. Following the sale, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 151,589 shares of company stock valued at $23,075,723. 2.10% of the stock is currently owned by corporate insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.